Advisors Asset Management, Inc. Exelixis, Inc. Transaction History

Advisors Asset Management, Inc.

$4.99 Billion
Q2 2024

A detailed history of Advisors Asset Management, Inc. transactions in Exelixis, Inc. stock. As of the latest transaction made, Advisors Asset Management, Inc. holds 19,244 shares of EXEL stock, worth $506,117. This represents 0.01% of its overall portfolio holdings.

Number of Shares

19,244

Previous 21,014 8.42%

Holding current value

$506,117

Previous $498,000 13.25%

% of portfolio

0.01%

Previous 0.01%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$20.34 - $23.73 $36,001 - $42,002	-1,770 Reduced 8.42%	19,244 $432,000
Q1 2024 May 14, 2024	BUY	$20.17 - $23.93 $111,197 - $131,926	5,513 Added 35.57%	21,014 $498,000
Q4 2023 Feb 14, 2024	BUY	$19.25 - $24.13 $37,056 - $46,450	1,925 Added 14.18%	15,501 $371,000
Q2 2023 Aug 14, 2023	SELL	$18.17 - $20.48 $50,603 - $57,036	-2,785 Reduced 17.02%	13,576 $259,000
Q1 2023 May 12, 2023	SELL	$16.3 - $19.41 $16,984 - $20,225	-1,042 Reduced 5.99%	16,361 $317,000
Q4 2022 Feb 13, 2023	SELL	$14.96 - $17.39 $174,089 - $202,367	-11,637 Reduced 40.07%	17,403 $279,000
Q3 2022 Nov 08, 2022	SELL	$15.68 - $22.27 $62,688 - $89,035	-3,998 Reduced 12.1%	29,040 $455,000
Q2 2022 Aug 08, 2022	SELL	$17.44 - $23.16 $228,900 - $303,975	-13,125 Reduced 28.43%	33,038 $688,000
Q1 2022 May 17, 2022	SELL	$17.03 - $22.67 $224,659 - $299,062	-13,192 Reduced 22.23%	46,163 $1.05 Million
Q4 2021 Feb 15, 2022	BUY	$15.84 - $21.88 $42,118 - $58,178	2,659 Added 4.69%	59,355 $1.09 Million
Q3 2021 Nov 12, 2021	BUY	$16.3 - $21.14 $41,190 - $53,420	2,527 Added 4.67%	56,696 $1.2 Million
Q2 2021 Jul 30, 2021	BUY	$17.95 - $25.56 $269,196 - $383,323	14,997 Added 38.28%	54,169 $987,000
Q1 2021 May 07, 2021	BUY	$20.53 - $25.22 $331,744 - $407,529	16,159 Added 70.22%	39,172 $885,000
Q4 2020 Feb 12, 2021	BUY	$18.39 - $24.8 $292,014 - $393,799	15,879 Added 222.58%	23,013 $462,000
Q3 2020 Nov 16, 2020	BUY	$20.67 - $26.94 $68,314 - $89,036	3,305 Added 86.31%	7,134 $174,000
Q2 2020 Aug 12, 2020	BUY	$16.46 - $27.42 $63,025 - $104,991	3,829 New	3,829 $91,000
Q3 2019 Nov 14, 2019	SELL	$17.68 - $22.65 $68,510 - $87,768	-3,875 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$18.93 - $24.75 $51,584 - $67,443	-2,725 Reduced 41.29%	3,875 $83,000
Q1 2019 May 15, 2019	SELL	$19.6 - $24.76 $51,548 - $65,118	-2,630 Reduced 28.49%	6,600 $157,000
Q4 2018 Jan 31, 2019	SELL	$13.65 - $21.8 $11,411 - $18,224	-836 Reduced 8.31%	9,230 $182,000
Q3 2018 Nov 15, 2018	BUY	$15.87 - $22.4 $2,920 - $4,121	184 Added 1.86%	10,066 $178,000
Q2 2018 Aug 22, 2018	SELL	$18.56 - $22.45 $580,668 - $702,370	-31,286 Reduced 76.0%	9,882 $213,000
Q2 2018 Aug 15, 2018	BUY	$18.56 - $22.45 $371,664 - $449,561	20,025 Added 94.71%	41,168 $213,000
Q1 2018 May 15, 2018	BUY	$22.15 - $31.89 $57,412 - $82,658	2,592 Added 13.97%	21,143 $545,000
Q4 2017 Feb 13, 2018	BUY	$24.23 - $30.93 $56,383 - $71,974	2,327 Added 14.34%	18,551 $564,000
Q3 2017 Nov 07, 2017	BUY	$23.35 - $29.24 $378,830 - $474,389	16,224	16,224 $393,000

Others Institutions Holding EXEL

# of Institutions

460

Shares Held

240M

Call Options Held

2.04M

Put Options Held

1.29M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $8.46B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisors Asset Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisors Asset Management, Inc. with notifications on news.

Account

Advisors Asset Management, Inc. Exelixis, Inc. Transaction History